|
2024
|
Invention
|
Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1... |
|
|
Invention
|
N-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)am... |
|
|
Invention
|
Fused pyrimidine compounds as inhibitors of menin. Disclosed herein are heterocyclic compounds th... |
|
|
Invention
|
Pyrazine compounds as inhibitors of flt3.
Disclosed herein are heterocyclic compounds that inhib... |
|
|
Invention
|
Crystalline forms of an irreversible inhibitor of menin-mll interaction.
Described herein is N-[... |
|
|
Invention
|
Crystalline forms of n[4[4-(4-morpholinyl)-7h-pyrrolo[2-3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-o... |
|
|
Invention
|
Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l... |
|
|
Invention
|
Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(... |
|
2023
|
Invention
|
Inhibitors of menin-mll interaction.
Disclosed herein are heterocyclic compounds that inhibit th... |
|
|
Invention
|
Substituted pyridines as irreversible inhibitors of menin-mll interaction. Disclosed herein are h... |
|
|
Invention
|
Menin-mll inhibitors and compositions for proliferation of beta cells. Methods and compositions u... |
|
|
Invention
|
Flt3 combination therapy for cancer and compositions therefor. Disclosed herein are combinations ... |
|
|
Invention
|
Irreversible inhibitors of menin-mll interaction. Disclosed herein are heterocyclic compounds tha... |
|
2022
|
Invention
|
Pyrazine compounds as inhibitors of flt3. Disclosed herein are heterocyclic compounds, for exampl... |
|
|
Invention
|
Pyrazine compounds as inhibitors of flt3. Disclosed herein are heterocyclic compounds that inhibi... |
|
|
Invention
|
Inhibitors of kras.
Disclosed herein are macrocyclic compounds that inhibit the binding of KRas.... |
|
|
Invention
|
Inhibitors of kras. Disclosed herein are macrocyclic compounds that inhibit the binding of KRas. ... |
|
|
Invention
|
Irreversible inhibitors of kras.
Disclosed herein are heterocyclic compounds that inhibit the bi... |
|
|
Invention
|
Irreversible inhibitors of kras. Disclosed herein are heterocyclic compounds that inhibit the bin... |
|
|
Invention
|
Pyrazine compounds as irreversible inhibitors of flt3. Disclosed herein are heterocyclic compound... |
|
|
Invention
|
Covalent inhibitors of menin-mll interaction for diabetes mellitus.
Disclosed herein are heteroc... |
|
|
Invention
|
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-... |
|
|
Invention
|
Covalent inhibitors of menin-mll interaction for diabetes mellitus. Disclosed herein are heterocy... |
|
|
Invention
|
Synthetic methods for preparing a pyridinecarboxamide compound. Described herein are synthetic me... |
|
|
P/S
|
Medical information; Providing information in the field of the diagnosis and treatment of cancer ... |
|
2021
|
Invention
|
Fused pyrimidine compounds as inhibitors of menin-mll interaction.
Disclosed herein are heterocy... |
|
|
Invention
|
Fused pyrimidine compounds as inhibitors of menin-mll interaction. Disclosed herein are heterocyc... |
|
|
Invention
|
Inhibitors of menin-mll interaction. Disclosed herein are heterocyclic compounds that inhibit the... |
|
|
P/S
|
Chemotherapeutics; Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma prepara... |
|
|
P/S
|
Chemotherapeutics; adjuvants for medical purposes; anti-cancer preparations; anti-sarcoma prepara... |
|
|
P/S
|
Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Cellular fun... |
|
2020
|
P/S
|
Providing a web site featuring medical information; Providing a website featuring information in ... |
|
|
P/S
|
Providing information on the subject of scientific research in the field
of biochemistry and biot... |
